Global Alliance for TB Drug Development   Report issue

Contributed to NME Foundation Phase 1 Phase 3
Founded: Cape Town South Africa (2000)

Organization Overview

First Clinical Trial
2006
NCT00144417
First Marketed Drug
2019
pretomanid
First NDA Approval
2019
pretomanid
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Global Alliance for TB Drug Development

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Extensively Drug-Resistant Tuberculosis (Phase 3)

Hypersensitivity (Phase 3)

Latent Tuberculosis (Phase 1)

Meningitis (Phase 2)

Tuberculosis (Phase 3)

Tuberculosis, Meningeal (Phase 2)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 33
  • # of Trial APIs: 20